Search Results
Isatuximab: a ‘next-generation monoclonal antibody’
2019 Multiple Myeloma Symposium | Novel and Next Generation Therapy
What is isatuximab? And how does it compare with daratumumab?
Isatuximab for multiple myeloma - promising results and next steps
Overview of a Phase II clinical trial of isatuximab
Daratumumab and isatuximab in the treatment of multiple myeloma
What does the FDA approval of Sarclisa® (isatuximab) mean for myeloma patients?
Where isatuximab may fit in the treatment paradigm for relapsed/refractory multiple myeloma
IKEMA trial update: Isatuximab in MM
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy for NDMM patients
The importance of anti-CD38 monoclonal antibodies for multiple myeloma
Daratumumab vs isatuximab in the treatment of multiple myeloma
